| Literature DB >> 30452903 |
Aithne Atkinson1, Alexander Renziehausen1, Hexiao Wang2, Cristiana Lo Nigro3, Laura Lattanzio3, Marco Merlano3, Bhavya Rao4, Lynda Weir4, Alan Evans5, Rubeta Matin6, Catherine Harwood6, Peter Szlosarek6, J Geoffrey Pickering7, Colin Fleming8, Van Ren Sim9, Su Li10, James T Vasta11, Ronald T Raines12, Mathieu Boniol13, Alastair Thompson14, Charlotte Proby15, Tim Crook16, Nelofer Syed17.
Abstract
Appropriate post-translational processing of collagen requires prolyl hydroxylation, catalyzed by collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase, and is essential for normal cell function. Here we have investigated the expression, transcriptional regulation, and function of the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families in melanoma. We show that the collagen prolyl 3-hydroxylase family exemplified by Leprel1 and Leprel2 is subject to methylation-dependent transcriptional silencing in primary and metastatic melanoma consistent with a tumor suppressor function. In contrast, although there is transcriptional silencing of P4HA3 in a subset of melanomas, the collagen prolyl 4-hydroxylase family members P4HA1, P4HA2, and P4HA3 are often overexpressed in melanoma, expression being prognostic of worse clinical outcomes. Consistent with tumor suppressor function, ectopic expression of Leprel1 and Leprel2 inhibits melanoma proliferation, whereas P4HA2 and P4HA3 increase proliferation, and particularly invasiveness, of melanoma cells. Pharmacological inhibition with multiple selective collagen prolyl 4-hydroxylase inhibitors reduces proliferation and inhibits invasiveness of melanoma cells. Together, our data identify the collagen prolyl 3-hydroxylase and collagen prolyl 4-hydroxylase families as potentially important regulators of melanoma growth and invasiveness and suggest that selective inhibition of collagen prolyl 4-hydroxylase is an attractive strategy to reduce the invasive properties of melanoma cells.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30452903 PMCID: PMC7015666 DOI: 10.1016/j.jid.2018.10.038
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551